{{Rsnum
|rsid=3862227
|Gene=TMLHE
|Chromosome=1
|position=43255323
|Orientation=plus
|GMAF=0.3604
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 37.5 | 48.2 | 14.3
| HCB | 24.3 | 48.5 | 27.2
| JPT | 18.0 | 48.6 | 33.3
| YRI | 85.0 | 14.3 | 0.7
| ASW | 64.9 | 35.1 | 0.0
| CHB | 24.3 | 48.5 | 27.2
| CHD | 17.8 | 47.7 | 34.6
| GIH | 27.3 | 48.5 | 24.2
| LWK | 87.3 | 11.8 | 0.9
| MEX | 47.3 | 36.4 | 16.4
| MKK | 70.5 | 25.0 | 4.5
| TSI | 35.3 | 53.9 | 10.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs3862227
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.32, combined P value= 5.53E-05. It is also associated with greater methotrexate clearance.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470174
}}

{{PMID Auto
|PMID=15986317
|Title=Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3862227
|overall_frequency_n=36
|overall_frequency_d=128
|overall_frequency=0.28125
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}